Osteoarthritis
Conditions
Brief summary
The aim of the study is to investigate * the indication for MOBEC in a dose of 15 mg per day * the treatments patients were receiving before switching to 15 mg MOBEC * how treatment with 15 mg is assessed compared with previous treatment * how effective and safe treatment with 15 mg MOBEC is considered
Interventions
DRUGMOBEC
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* An indication for a treatment with 15 mg MOBEC of at least four weeks * the symptomatic short-term treatment of osteoarthritis * the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg) * the symptomatic treatment of ankylosing spondylitis
Exclusion criteria
* Treatment with MOBEC prior to the start of the study * Patients with any of the general or specific contraindications of MOBEC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nature and incidence of adverse drug reactions (ADR) | up to week 8 |
| Assessment of efficacy by physician on a 5-point scale | up to week 8 |
| Assessment of tolerability by physician on a 5-point scale | up to week 8 |
Outcome results
None listed